Avanir Pharmaceuticals (NASDAQ: AVNR) provided updates on its two license and collaboration agreements and announced certain restructuring activities intended to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE